Determination of a weight-adjusted dose of TNK-tissue plasminogen activator

American Heart Journal

Volumn 141, Issue 1, 2001, Pages 33-40

  Wang Clow, Fong ^a   Fox, Norma Lynn ^a   Cannon, Christopher P ^c   Gibson, C Michael ^b   Berioli, Silvano ^d   Bluhmki, Erich ^d   Danays, Thierry ^d   Braunwald, Eugene ^c   Van De Werf, Frans ^e   Stump, David C ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TENECTEPLASE;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW RATE; HUMAN; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEADY STATE;

EID: 0035169698     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.112092     Document Type: Article

References (18)

1. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial
2. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction
3. A faster-acting and more potent form of tissue plasminogen activator
4. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
5. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
6. Weight adjusted dosing af TNK-tissue plasminogen activator and its relationship to angiographic outcomes in the TIMI 10B trial
7. TIMI frame count: A quantitative method of assessing coronary artery flow
8. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
9. Safety assessment of single-bolus administration of TNK tissue plasminogen activator in acute myocardial infarction: The ASSENT-I trial
10. The relationship between the TIMI Frame Count and clinical outcomes after thrombolytic administration
11. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study
12. GISSI-2: A factorial randomised trial of alterplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction
13. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
14. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-I trial
15. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators
16. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction
17. Abciximab facilitates the rate and the extent of thrombolysis: Results of TIMI 14 trial
18. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial